Introducing MetVax.

D5Pharma’s groundbreaking new cancer vaccine, MetVax, capitalizes on a precisely defined protein fragment of carcinoembryonic antigen—a well-established mediator of adhesion and tumor implantation— to block metastasis. Read More

Targeting CD200R1 with PEG:CCS13.

Our patented aptamers have demonstrated benefits in animal models of disease. D5Pharma’s lead drug candidate is PEG:CCS13, a PEGylated single-stranded DNA aptamer that is a selective agonist for the inflammatory modulator, CD200R1, a glycoprotein receptor found on the...